SCM
ATOS icon

Sterling Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Sterling Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-127
Closed -$1.28K – 3277
2025
Q1 		$1.28K Sell
127
-112
-47% -$1.36K ﹤0.01% 2731
2024
Q4 		$3.38K Buy
239
+215
+896% +$4.2K ﹤0.01% 2610
2024
Q3 		$540 Buy
+24
New +$484 ﹤0.01% 2837

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sterling Capital Management's ATOS Position: Q2 2025 in Review

Sterling Capital Management sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 127 shares — an estimated $1.28K sold.

Sterling Capital Management first reported a position in ATOS in Q3 2024 and held it in 3 quarters. The position peaked at $3.38K in Q4 2024. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Sterling Capital Management reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 127 Atossa Therapeutics shares in Q2 2025, an estimated $1.28K.
  • Sterling Capital Management first reported a position in Atossa Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Atossa Therapeutics position peaked at $3.38K in Q4 2024.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.